-
Markets
-
Aktien
Sustainable finance2025 Euronext ESG Trends ReportWeiterlesenA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesWeiterlesenThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeWeiterlesenInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondWeiterlesenFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesWeiterlesenTrade mini bond futures on main European government bonds
-
Rohstoffe
- Übersicht
- Kurse überblick
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesWeiterlesenEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameWeiterlesenJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Adocia
Identification
Instrument name
ADOCIA
Symbol
ADOC
ISIN code
FR0011184241
Exchange / Market
Euronext
Trading location
Paris
Products family
Stocks
ICB
Biotechnology
Activity description
Adocia est spécialisé dans la recherche et le développement de produits biothérapeutiques destinés à la régénération des tissus et au traitement de maladies chroniques.
A fin juin 2011, le groupe dispose d’un portefeuille de 4 produits en développement clinique (dont 2 en phase II ; PDGF-BB pour le traitement des ulcères du pied diabétique et HinsBet, insuline humaine à action rapide pour le traitement du diabète).
Website address
www.adocia.com
Operation
IPO date
Mo. 20/02/2012
IPO type
Introduction par offre publique
IPO type
Initial Public offering
Catégorie
IPO
Operation calendar
LISTING DATE: 14/02/2012
TRADING DATE: 20/02/2012
Price range
Fourchette de prix indicative : 13,00 EUR - 15,88 EUR par action (le "Prix de l'Offre")